Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OriCAR-017 in R/RMM
NCT06182696Phase 2Recruiting
- Sponsor
- OriCell Therapeutics
- Start
- Oct 2023
- Primary completion
- Nov 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oricar-017 in multiple myeloma (MM), sponsored by OriCell Therapeutics. Primary endpoints: Maximum Tolerated Dose at 28 days and Dose-Limiting Toxicity at 28 days. Started Oct 2023; status: recruiting.
02
Drugs
oricar-017
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06182696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06182696.